Table 3 Multivariable analysis of factors associated with pathologic complete response (pCR)
Characteristic | Univariate analysis | Multivariable analysis | |||
|---|---|---|---|---|---|
No pCR n = 1045 | pCR n = 381 | p | Odds ratio (95% CI) | p | |
Age | 50 (42–60) | 51 (41–59) | 0.9 | ||
Race | 0.8 | ||||
Black | 149 (75%) | 50 (25%) | |||
Asian, Native American, or other | 174 (72%) | 68 (28%) | |||
White | 636 (73%) | 239 (27%) | |||
Unknown | 86 | 24 | |||
Clinical T stage | 0.028 | ||||
T1 | 148 (70%) | 62 (30%) | |||
T2 | 565 (72%) | 217 (28%) | |||
T3 | 228 (81%) | 55 (19%) | |||
T4 | 99 (72%) | 39 (28%) | |||
Unknown | 5 | 8 | |||
cN+ | 718 (75%) | 234 (25%) | 0.010 | ||
BRCA status | 0.001 | ||||
Noncarrier | 934 (74%) | 327 (26%) | ref. | ref. | |
BRCA1 | 53 (58%) | 39 (42%) | 2.37 (1.32–4.18) | 0.003 | |
BRCA2 | 58 (79%) | 15 (21%) | 1.56 (0.71–3.23) | 0.2 | |
Differentiation | <0.001 | ||||
Poor | 660 (66%) | 339 (34%) | ref. | ref. | |
Well/moderate | 380 (91%) | 37 (8.9%) | 0.32 (0.19–0.52) | <0.001 | |
Unknown | 5 | 5 | |||
Histology | <0.001 | ||||
Ductal | 935 (73%) | 351 (27%) | |||
Lobular/mixed | 101 (87%) | 15 (13%) | |||
Unknown | 9 | 15 | |||
Receptor subtype | <0.001 | ||||
HR+/HER2− | 482 (92%) | 40 (8%) | ref. | ref. | |
TN | 278 (68%) | 133 (32%) | 3.95 (2.32–6.97) | <0.001 | |
HR+/HER2+ | 219 (69%) | 98 (31%) | 6.16 (3.60–10.9) | <0.001 | |
HR−/HER2+ | 66 (37.5%) | 110 (62.5%) | 21.6 (12.0–40.1) | <0.001 | |
Neoadjuvant regimen | 0.4 | ||||
ACT-based | 969 (74%) | 345 (26%) | |||
Taxane/platinum/CMF | 74 (70%) | 32 (30%) | |||
Unknown | 2 | 4 | |||
Carboplatin receipt | 122 (67%) | 60 (33%) | 0.041 | ||
Lymphovascular invasion | 367 (88%) | 48 (12%) | <0.001 | 0.48 (0.32–0.69) | <0.001 |
Unknown | 181 | 149 | |||
